ST Renfu: The holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" RFUS-1646 tablets issued and approved by the National Medical Products Administration.

2026-04-09 21:15:23

ST Renfu Announcement: The holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” RFUS-1646 Tablets issued and approved by the National Medical Products Administration. The drug name is RFUS-1646 tablets, dosage form is tablets, and the application is for domestic production drug registration clinical trials. The registration category is Class 1 chemical drug. RFUS-1646 tablets is a new molecular entity independently developed by Yichang Renfu, intended for clinical use in the treatment of acute pain (such as postoperative pain). As of now, Yichang Renfu has invested approximately 14 million RMB in research and development for this project.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.